Creating a database for patients with immune-mediated inflammatory diseases
Deployment o the Multidisciplinary Prospective Cohort Imminent
NA · University Hospital, Lille · NCT04334031
This study is creating a database and biobank for patients with immune-related diseases to see if new information can help improve treatments and understand their conditions better.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 2200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Lille (other) |
| Locations | 1 site (Lille) |
| Trial ID | NCT04334031 on ClinicalTrials.gov |
What this trial studies
This study aims to establish a multidisciplinary clinical-biological database and biobank for patients suffering from immune-mediated inflammatory diseases (IMIDs) such as chronic inflammatory disease, angioedema, severe asthma, lupus, and atopic dermatitis. By collecting data and biological samples, the study seeks to identify new prognostic and therapeutic biomarkers that could lead to improved treatment strategies. Patients will be assessed using the SF-12 questionnaire to evaluate their quality of life and disease severity. The research will involve collaboration among various departments at Lille University Hospital.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with an IMID who are being treated at Lille University Hospital and can provide informed consent.
Not a fit: Patients who are pregnant, breastfeeding, or unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the development of new therapeutic targets and improved management of immune-mediated inflammatory diseases.
How similar studies have performed: Other studies have shown promise in identifying biomarkers for IMIDs, but this approach of creating a comprehensive database is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient followed for their IMID in one of the departments of the Lille University Hospital participating in the study (dermatology, internal medicine, neurology, pneumology and rheumatology) * Social insured * Have the capacity to understand the study requirements, provide written informed consent, and comply with the study data collection procedures. Exclusion Criteria: * Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of coverage by the social security system. * Pregnant or breastfeeding woman * Persons deprived of liberty * Protected minors or adults * Persons who have refused or are incapable of giving informed consent * Persons in Emergency Situations
Where this trial is running
Lille
- Hop Claude Huriez Chu Lille — Lille, France (RECRUITING)
Study contacts
- Principal investigator: David Launay, MD,PhD — University Hospital, Lille
- Study coordinator: David Launay, MD,PhD
- Email: david.launay@chru-lille.fr
- Phone: 03 20 44 42 95
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Chronic Inflammatory Disease, Angioedema, Severe Asthma, Lupus, Atopic Dermatitis, Psoriatic Arthritis, Multiple Sclerosis, Systemic Sclerosis